CNS Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
CNS Pharmaceuticals's earnings have been declining at an average annual rate of -23%, while the Pharmaceuticals industry saw earnings growing at 1% annually.
Key information
-23.0%
Earnings growth rate
15.7%
EPS growth rate
Pharmaceuticals Industry Growth | 6.0% |
Revenue growth rate | n/a |
Return on equity | n/a |
Net Margin | n/a |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
CNS Pharmaceuticals reports Q2 results
Aug 15Here's Why We're A Bit Worried About CNS Pharmaceuticals' (NASDAQ:CNSP) Cash Burn Situation
Dec 04CNS Pharmaceuticals sinks after pricing equity offering of $10M
Dec 23How Many CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Shares Did Insiders Buy, In The Last Year?
Dec 09Revenue & Expenses BreakdownBeta
How CNS Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 0 | -19 | 5 | 14 |
30 Sep 23 | 0 | -19 | 6 | 13 |
30 Jun 23 | 0 | -18 | 6 | 12 |
31 Mar 23 | 0 | -17 | 6 | 11 |
31 Dec 22 | 0 | -15 | 6 | 9 |
30 Sep 22 | 0 | -13 | 5 | 9 |
30 Jun 22 | 0 | -14 | 5 | 9 |
31 Mar 22 | 0 | -14 | 5 | 9 |
31 Dec 21 | 0 | -14 | 5 | 10 |
30 Sep 21 | 0 | -14 | 5 | 9 |
30 Jun 21 | 0 | -12 | 5 | 8 |
31 Mar 21 | 0 | -11 | 4 | 7 |
31 Dec 20 | 0 | -9 | 4 | 5 |
30 Sep 20 | 0 | -9 | 4 | 5 |
30 Jun 20 | 0 | -8 | 4 | 4 |
31 Mar 20 | 0 | -6 | 3 | 2 |
31 Dec 19 | 0 | -4 | 2 | 2 |
30 Sep 19 | 0 | -8 | 1 | 0 |
30 Jun 19 | 0 | -7 | 1 | 0 |
31 Mar 19 | 0 | -7 | 1 | 0 |
31 Dec 18 | 0 | -7 | 1 | 0 |
Quality Earnings: CNSP is currently unprofitable.
Growing Profit Margin: CNSP is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CNSP is unprofitable, and losses have increased over the past 5 years at a rate of 23% per year.
Accelerating Growth: Unable to compare CNSP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CNSP is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.5%).
Return on Equity
High ROE: CNSP's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.